Related Experiment Video
Updated: Sep 4, 2026
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
The no-reflow phenomenon: State of the art
Claire Bouleti1, Nathan Mewton2, Stéphane Germain3
1Service de cardiologie, hôpital Bichat, AP-HP, Paris, France; DHU FIRE, université Paris Diderot, Paris, France; Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris, France; CNRS/UMR 7241, Paris, France; Inserm U 1050, Paris, France.
Insights
Primary percutaneous coronary intervention (PCI) effectively reopens blocked arteries in ST-segment elevation myocardial infarction (STEMI). However, microvascular no-reflow (NR) can still occur, hindering optimal reperfusion and patient outcomes.
Area of Science:
- Cardiology
- Vascular Biology
- Biomedical Science
Background:
- Primary percutaneous coronary intervention (PCI) is the gold standard for reperfusion in ST-segment elevation myocardial infarction (STEMI).
- Despite successful epicardial artery reopening, microvascular dysfunction, termed no-reflow (NR), occurs in up to 60% of STEMI patients.
- No-reflow significantly impairs the benefits of reperfusion therapy, leading to adverse clinical outcomes.
Purpose of the Study:
- To review the complex pathophysiology of no-reflow (NR) in STEMI.
- To discuss diagnostic tools for identifying NR.
- To explore microvascular and endothelial mechanisms underlying NR for potential therapeutic targets.
Main Methods:
- Literature review of pathophysiological mechanisms of no-reflow.
- Analysis of diagnostic methods for NR.
- Examination of microvascular and endothelial dysfunction in STEMI.
Main Results:
- No-reflow is a multifactorial condition involving leukocyte infiltration, vasoconstriction, inflammation, and edema.
- Vascular damage and hemorrhage contribute to the development of NR.
- Understanding these mechanisms is crucial for developing targeted therapies.
Conclusions:
- No-reflow remains a significant challenge in STEMI management despite advances in primary PCI.
- Identifying and targeting microvascular and endothelial dysfunction is key to improving outcomes.
- Further research into NR pathophysiology may reveal novel therapeutic strategies.
Abstract:
Primary percutaneous coronary intervention (PCI) is the best available reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI), with nearly 95% of occluded coronary vessels being reopened in this setting. Despite re-establishing epicardial coronary vessel patency, primary PCI may fail to restore optimal myocardial reperfusion within the myocardial tissue, a failure at the microvascular level known as no-reflow (NR). NR has been reported to occur in up to 60% of STEMI patients with optimal coronary vessel reperfusion. When it does occur, it significantly attenuates the beneficial effect of reperfusion therapy, leading to poor outcomes. The pathophysiology of NR is complex and incompletely understood. Many phenomena are known to contribute to NR, including leukocyte infiltration, vasoconstriction, activation of inflammatory pathways and cellular oedema. Vascular damage and haemorrhage may also play important roles in the establishment of NR. In this review, we describe the pathophysiological mechanisms of NR and the tools available for diagnosing it. We also describe the microvasculature and the endothelial mechanisms involved in NR, which may provide relevant therapeutic targets for reducing NR and improving the prognosis for patients.
